The same can be said of MD3100 from MDVN since they just had the open label phase 1/2 and no controlled study. Except the market "value" of MD3100 is a lot more then TH-302. I don't know if they did a TH-302 mono trial for pancreatic cancer - and I dont think they did, but it's been a while since I looked.
Still the HAP moa hasn't been proven by any company so the chances are slim that it will be Threshold that figures it out, but I was looking at the data they presented today and the same data presented back in Jan and the complete response was new as were a number or partial responses.
gemcitabine itself that was entirely responsible for the CR and the additional PRs
I don't know if it's still the case now that it is widely used, but the trials which formed the basis for gemcitabine's approval had zero objective responses.
Market Data 
Markets 
AI
